Brooks Labs - Brooks Laboratories Share Price

66.561.52 (2.33%)

Closed
As On: 12 Jun, 2026, 03:55 PM IST
As On: 12 Jun, 2026, 03:55 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	65.05
High	66.89
Low	65.00
Prev Close	65.05
Volume	8,912
VWAP(₹)	65.94

Share Price	Value
Today/Current/Last	66.5666.39
Previous Day	65.0565.25

Brooks Labs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Brooks Labs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	20.65	16.69	23.84	25.73	23.94
Total Income Growth (%)	23.70	-29.99	-7.34	7.48	-37.90
Total Expenses	19.94	16.23	21.32	22.78	22.16
Total Expenses Growth (%)	22.91	-23.89	-6.40	2.77	-40.70
EBIT	0.70	0.46	2.52	2.95	1.77
EBIT Growth (%)	51.58	-81.59	-14.61	66.46	51.59
Profit after Tax (PAT)	1.52	5.50	7.98	9.58	-1.46
PAT Growth (%)	-72.30	-31.07	-16.78	-	-
EBIT Margin (%)	3.41	2.78	10.57	11.47	7.41
Net Profit Margin (%)	7.38	32.94	33.46	37.25	-6.09
Basic EPS (₹)	0.52	1.87	2.71	3.25	-0.54

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	20.65	16.69	23.84	25.73	23.94
Total Income Growth (%)	23.70	-29.99	-7.34	7.48	-37.90
Total Expenses	19.94	16.23	21.32	22.78	22.13
Total Expenses Growth (%)	22.91	-23.89	-6.40	2.93	-40.79
EBIT	0.70	0.46	2.52	2.95	1.81
EBIT Growth (%)	51.58	-81.59	-14.61	63.20	54.61
Profit after Tax (PAT)	0.61	0.30	2.24	2.65	1.37
PAT Growth (%)	102.87	-86.47	-15.59	93.15	89.49
EBIT Margin (%)	3.41	2.78	10.57	11.47	7.56
Net Profit Margin (%)	2.98	1.81	9.38	10.30	5.73
Basic EPS (₹)	0.21	0.10	0.76	0.90	0.51

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	86.91	83.44	80.44	63.41	91.99
Total Revenue Growth (%)	4.16	3.73	26.86	-31.07	17.96
Total Expenses	81.10	80.25	78.89	98.83	115.88
Total Expenses Growth (%)	1.07	1.72	-20.18	-14.71	33.25
Profit after Tax (PAT)	24.58	-9.97	-19.59	-20.90	-16.19
PAT Growth (%)	-	-	-	-	-
Operating Profit Margin (%)	7.74	5.11	3.01	-52.59	-22.83
Net Profit Margin (%)	28.67	-12.07	-24.64	-33.06	-17.77
Basic EPS (₹)	8.35	-3.72	-7.65	-12.57	-7.82

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	86.91	83.44	80.44	55.65	77.91
Total Revenue Growth (%)	4.16	3.73	44.56	-28.58	-0.41
Total Expenses	81.10	80.21	78.89	63.84	77.25
Total Expenses Growth (%)	1.11	1.68	23.58	-17.36	-10.87
Profit after Tax (PAT)	5.81	3.05	1.53	-8.19	0.67
PAT Growth (%)	90.19	99.66	-	-1,329.91	-
Operating Profit Margin (%)	7.74	5.15	3.01	-13.36	1.73
Net Profit Margin (%)	6.77	3.69	1.92	-14.74	0.86
Basic EPS (₹)	1.97	1.14	0.58	-3.32	0.27

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 17.68% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	148.17	123.69	90.45	109.60	195.91
Total Assets Growth (%)	19.79	36.76	-17.47	-44.06	20.87
Total Liabilities	25.52	25.59	24.86	35.64	61.59
Total Liabilities Growth (%)	-0.29	2.94	-30.25	-42.13	-25.73
Total Equity	122.66	98.10	65.59	73.95	134.32
Total Equity Growth (%)	25.03	49.58	-11.32	-44.94	69.71
Current Ratio (x)	1.72	1.48	1.35	0.84	1.25
Total Debt to Equity (x)	0.06	0.06	0.08	0.08	0.38
Contingent Liabilities	0.00	77.48	72.29	20.84	7.97

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	146.36	140.66	94.39	92.42	103.45
Total Assets Growth (%)	4.05	49.02	2.13	-10.66	11.24
Total Liabilities	25.52	25.59	24.86	35.64	38.45
Total Liabilities Growth (%)	-0.27	2.94	-30.25	-7.31	33.55
Total Equity	120.84	115.07	69.53	56.78	65.00
Total Equity Growth (%)	5.01	65.50	22.46	-12.65	1.23
Current Ratio (x)	1.72	1.48	1.35	0.84	1.04
Total Debt to Equity (x)	0.06	0.05	0.07	0.10	0.08
Contingent Liabilities	0.00	77.48	72.29	20.84	24.79

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	9.29	2.63	-9.68	-14.49	-37.44
Net Cash used in Investing Activities	-2.92	-45.14	0.18	0.49	-24.91
Net Cash flow from Financing Activities	0.17	42.43	9.60	11.41	64.07
Net Cash Flow	6.54	-0.08	0.10	-2.58	1.72
Closing Cash & Cash Equivalent	6.59	0.04	0.13	0.02	2.61
Closing Cash & Cash Equivalent Growth (%)	0.00	-65.42	438.63	-99.11	194.72
Total Debt/ CFO (x)	0.78	2.31	-0.52	-0.39	-0.65

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	9.29	2.63	-9.68	0.56	3.12
Net Cash used in Investing Activities	-2.92	-45.14	0.18	-0.40	1.12
Net Cash flow from Financing Activities	0.17	42.43	9.60	-0.22	-4.22
Net Cash Flow	6.54	-0.08	0.10	-0.06	0.02
Closing Cash & Cash Equivalent	6.59	0.04	0.13	0.02	0.08
Closing Cash & Cash Equivalent Growth (%)	0.00	-65.42	440.95	-72.32	31.55
Total Debt/ CFO (x)	0.78	2.31	-0.52	10.07	1.58

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 9.29 cr is 0.38 times compared to the reported net profit of Rs 24.58 cr. (Source: Consolidated Financials)
Decrease in Cash from Investing
Company has used Rs 2.92 cr for investing activities which is an YoY decrease of 93.53%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	20.04	-10.15	-29.87	-28.26	-25.67
Return on Capital Employed (%)	5.25	4.18	3.56	-43.41	-14.14
Return on Assets (%)	16.59	-8.05	-21.66	-19.06	-8.26
Interest Coverage Ratio (x)	9.85	5.66	4.94	-12.01	-4.34
Asset Turnover Ratio (x)	0.63	0.77	0.79	0.41	0.58
Price to Earnings (x)	4.49	-31.95	-12.44	-7.40	-11.09
Price to Book (x)	0.90	3.24	3.71	2.09	2.84
EV/EBITDA (x)	13.39	55.34	59.41	-6.07	-20.15
EBITDA Margin (%)	9.59	7.05	5.24	-41.47	-14.76

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	4.80	2.65	2.19	-14.42	1.02
Return on Capital Employed (%)	5.33	3.61	3.36	-12.49	1.96
Return on Assets (%)	3.96	2.16	1.61	-8.86	0.64
Interest Coverage Ratio (x)	9.85	5.70	4.94	-7.44	4.21
Asset Turnover Ratio (x)	0.60	0.70	0.85	0.57	0.78
Price to Earnings (x)	19.05	104.17	161.29	-18.90	270.27
Price to Book (x)	0.91	2.76	3.50	2.72	2.76
EV/EBITDA (x)	13.39	55.01	59.41	-27.90	64.91
EBITDA Margin (%)	9.59	7.09	5.24	-10.27	3.66

Insights

ROE Outperforming 5 Year Average
Company delivered ROE of 20.04% in year ending Mar 31, 2026 outperforming its 5 year avg. of -9.94%. (Source: Consolidated Financials)

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Brooks Labs	7.98	1.60	20.04	5.25	16.59	10.96	7.74	6.77	8.35	1.72	0.06	0.78
Venus Remedies	23.37	3.62	15.48	19.39	12.03	11.28	17.43	13.35	76.89	2.44	0.00	0.00
Kilitch Drug	21.91	2.39	10.78	13.15	6.59	19.85	18.77	12.52	8.91	1.83	0.32	3.70
Zim Laboratories	104.83	2.07	1.97	6.13	1.08	-1.59	5.71	1.55	1.19	1.45	0.42	2.48
SMS Lifesciences Ind	24.56	1.85	8.10	10.61	3.80	1.79	9.47	5.33	57.26	1.04	0.51	2.92
Add More

Annual Ratios (%)

Choose from Peers

Albert David
Bafna Pharma
Medico Remedies
Medicamen Bio
Lyka Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Brooks Labs Stock Performance	2.33	38.67	3.94	-10.62	-51.22	6.75	-30.74
Venus Remedies Stock Performance	4.81	91.69	75.54	136.72	413.72	797.40	460.32
Kilitch Drug Stock Performance	3.99	21.90	31.65	20.45	-19.86	72.82	131.71
Zim Laboratories Stock Performance	2.14	14.38	35.82	61.61	29.21	11.65	0.00
SMS Lifesciences Ind Stock Performance	0.23	-12.71	6.94	8.17	8.60	149.70	131.36
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	1,55,00,292	52.62 %	0.00
Pledge	0	0.00 %	0.00
FII	48,792	0.17 %	0.08
DII	29,16,111	9.90 %	0.00
MF	29,16,111	9.90 %	0.00
Others	1,09,92,053	37.31 %	-0.07

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	52.62	52.62	52.62	52.62
Pledge	0.00	0.00	0.00	0.00
FII	0.17	0.09	0.01	0.00
DII	9.90	9.90	9.90	9.90
Mutual Funds	9.90	9.90	9.90	9.90
Others	37.31	37.39	37.47	37.48

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Quant Business Cycle Direct-G
Equity: Thematic-Business Cycle
- 16.32
  Amount Invested (in Cr.)
- 1.692211%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Board Meeting
Quarterly Results
May 22, 2026
Board Meeting
Quarterly Results
Jan 29, 2026
Board Meeting
Quarterly Results
Nov 07, 2025

Board Meetings

Announced on	Meeting on
May 22, 2026	May 29, 2026
Quarterly Results
Jan 29, 2026	Feb 06, 2026
Quarterly Results
Nov 07, 2025	Nov 14, 2025
Quarterly Results
Aug 07, 2025	Aug 13, 2025
Quarterly Results
May 23, 2025	May 28, 2025
Audited Results

Dividends
No Data Available
Bonus
No Data Available
Splits
No Data Available
Rights
Announced on Ex-Date
Jan 25, 2023 Jul 28, 2023
Rights ratio: 1 share for every 16 held at a price of Rs 75.0
Jun 11, 2019 Feb 11, 2020
Rights ratio: 9 share for every 20 held at a price of Rs 20.0
AGM/EGM Meetings
Announced on Meeting on
Sep 08, 2025 Sep 26, 2025
-
Dec 19, 2024 Jan 11, 2025
-
Sep 02, 2024 Sep 19, 2024
A.G.M.
Sep 01, 2023 Sep 21, 2023
A.G.M.
Jan 31, 2023 Mar 05, 2023
-

Announced on	Ex-Date
Jan 25, 2023	Jul 28, 2023
Rights ratio: 1 share for every 16 held at a price of Rs 75.0
Jun 11, 2019	Feb 11, 2020
Rights ratio: 9 share for every 20 held at a price of Rs 20.0

Announced on	Meeting on
Sep 08, 2025	Sep 26, 2025
-
Dec 19, 2024	Jan 11, 2025
-
Sep 02, 2024	Sep 19, 2024
A.G.M.
Sep 01, 2023	Sep 21, 2023
A.G.M.
Jan 31, 2023	Mar 05, 2023
-

About Brooks Labs

Brooks Laboratories Ltd., incorporated in the year 2002, is a Small Cap company (having a market cap of Rs 196.07 Crore) operating in Pharmaceuticals sector.

Brooks Laboratories Ltd. key Products/Revenue Segments include Drugs, Export Incentives and Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 20.65 Crore, up 23.70 % from last quarter Total Income of Rs 16.69 Crore and down 13.74 % from last year same quarter Total Income of Rs 23.94 Crore. Company has reported net profit after tax of Rs .61 Crore in latest quarter.

The company’s top management includes Mr.Bhushan Singh Rana, Mr.Durga Shankar Maity, Mr.Jitendra Pratap Singh, Mr.Lalit Mahajan, Mr.Manav Mahajan, Dr.Usha Singh, Mr.Prashant Rathi, Ms.Krutika Rane. Company has S G C O & Co. LLP as its auditors. As on 31-03-2026, the company has a total of 2.95 Crore shares outstanding.

Brooks Labs Share Price Today is Rs. 66.56. On previous day, the Brooks Labs Share Price (NSE) closed at Rs. 65.05, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 52.62% of the stake in Brooks Labs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Brooks Labs stocks was 0.17% as compared to 0.09% in Dec 2025 with increase of 0.08%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 9.9% as compared to 9.9% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Brooks Labs shares 9.9% was held by mutual funds. The rest including public held is 37.31%. Brooks Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Brooks Labs Dividend: Ever since 2002, Brooks Labs dividends has been paid out around 0 times. As on 12 Jun, 2026, 03:55 PM IST, The overall dividend yield for Brooks Labs stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 8.35.

Brooks Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 20.65 Cr. of sales and 23.7% of quarterly net profit, there have been multiple ups and downs in the Brooks Labs stock prices in the past few weeks. For example, Brooks Labs stock price on 5th of June 2026 was around Rs. 65.68. Brooks Labs share price now stands at an average of Rs. 66.56. Judging by last week's performance, stock is in down trend.

Brooks Labs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Brooks Labs share.

Historical Prices and Performance:
Brooks Labs, incorporated in 2002 is a Small Cap company (with a market cap of Rs. 196.07) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Brooks Labs stock was 20.04%, -10.15%, -29.87%, -28.26% and -25.67% respectively.
The Brooks Labs share gave a 3 year return of 5.99% as compared to Nifty 50 which gave a return of 26.99%.
Brooks Labs announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Brooks Labs is 7.98
Prices/Sales Ratio of Brooks Labs is 1.29
Price/Book Ratio of Brooks Labs is 1.6

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Brooks Labs, major competitors and peers include Venus Remedies, Kilitch Drug, Zim Laboratories and SMS Lifesciences Ind. As of Dec 2025, the dividend yield of Brooks Labs stands at 0.0% while Venus Remedies, Kilitch Drug, Zim Laboratories and SMS Lifesciences Ind stand at 0.56%, 0.0%, 0.0% and 0.11% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 7.98 and 1.6 respectively.

Leadership of Brooks Labs :
Prashant Rathi is Chief Financial Officer
Krutika Rane is Co. Secretary & Compl. Officer
Bhushan Singh Rana is Whole Time Director
Jitendra Pratap Singh is Whole Time Director
Durga Shankar Maity is Whole Time Director
Manav Mahajan is Independent Director
Lalit Mahajan is Independent Director
Usha Singh is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Village Kishanpura,.Nalagarh Road,Solan District, Himachal Pradesh - 174101

Contact

investors@brookslabs.net

http://www.brookslabs.net

PE Ratio(x)	7.98
EPS - TTM(₹)	8.35
MCap(₹ Cr.)	196.07
MCap Rank	106
PB Ratio(x)	1.63
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	164.02
52W Low(₹)	36.30
MCap/Sales	1.29
Beta(1 Month)	1.98
BV/Share(₹)	41.64

PE Ratio(x)	7.96
EPS - TTM(₹)	8.35
MCap(₹ Cr.)	195.57
MCap Rank	120
PB Ratio(x)	1.58
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	165.95
52W Low(₹)	36.90
MCap/Sales	1.29
Beta(1 Month)	1.72
BV/Share(₹)	41.64

1 Day	2.33%
1 Month	33.63%
3 Months	7.04%
1 Year	-47.17%
3 Years	5.99%
5 Years	-34.29%

1 Day	1.74%
1 Month	33.37%
3 Months	5.78%
1 Year	-47.1%
3 Years	5.85%
5 Years	-34.33%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Brooks Labs - Brooks Laboratories Share Price

Key Metrics

Brooks Labs share price insights

Brooks Labs Share Price Returns

Brooks Labs Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Quant Business Cycle Direct-G

Brooks Labs Top Searches

Corporate Actions

About Brooks Labs

Executive Leadership

Auditors

FAQs about Brooks Labs share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News